Amneal appoints EVP, chief commercial officer of specialty
Amneal has appointed Gustavo Pesquin as executive vice president, chief commercial officer, specialty, effective Sept. 6.
Pesquin joins Amneal from Sanofi, where he served leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America head for general medicines.
Prior to that, Pesquin was the global head of diabetes and cardiovascular franchise. He also previously served as the global head of Sanofi’s Iberia and LATAM businesses. Before joining Sanofi, Pesquin held regional head, general manager, sales head and strategy head roles in Abbott and Pfizer, brand management roles at Procter & Gamble, and consultant roles with The Boston Consulting Group.
[Read more: Amneal debuts 2 generics]
Pesquin received a Master of Business Administration degree with a concentration in management and strategy, finance and accounting from Kellogg GSM, at Northwestern University and a Bachelor of Arts degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
“We are very pleased to welcome Gustavo as our chief commercial officer for specialty,” Amneal co-CEOs Chirag Patel and Chintu Patel said. “Gustavo brings world-class experience in building and leading the rapid and sustained growth of various therapeutic divisions at leading healthcare companies including Sanofi, Abbott and Pfizer. We believe his unique experience and breadth of knowledge in this area will help lead the specialty business through its next phase of growth.”
[Read more: FDA approves biosimilar Neupogen]
“I am very excited to join the Amneal team at this dynamic time," said Pesquin. “The company’s robust and advancing pipeline presents an exceptional opportunity to drive meaningful growth in the specialty segment and further expand and diversify the business. I look forward to working closely with Chirag and Chintu, the broader executive team, and all the field teams that have built Amneal into the successful company it is today.”